Akribion Therapeutics
Paul Scholz is a Co-Founder and Head of R&D at Akribion Therapeutics since December 2024. Prior to this role, Paul held various titles at BRAIN AG from May 2016 to December 2024, including Platform Head of Applied Bioinformatics, Program Manager of Genome Editing, and Project Manager. Paul's academic background includes a Ph.D. in Biology obtained from Ruhr University Bochum between 2012 and 2015. Additional experience includes a postdoctoral fellowship at Ruhr-Universität Bochum and a student internship at the University of Florida in early 2009.
This person is not in any teams
Akribion Therapeutics
Akribion Therapeutics is an early stage Biotech company developing precision oncology treatments. Using a groundbreaking new class of guided cytotoxic nucleases, Akribion aims to broaden the treatment landscape in critical therapeutic areas, with an initial focus in oncology through the use of highly selective cell depletion technology, enabled by specific targeting of RNA biomarkers. This unique technology platform is based on a proprietary family of nucleases termed G-dase® E. Akribion is committed to using its technology to improve patient treatment in compliance with high ethical standards. Akribion Therapeutics has been founded in 2024 by an expert team of scientists and Biotech executives, and is headquartered in Zwingenberg, Germany.